Institute for Molecular Intelligence™

Powering AI's Fundamental ability to perceive Drug Discovery Chemistry

The power of AI in the design and optimization of new medicines is on the cusp of launching into a new era. 

This requires the successful fusion of deep biology and deep chemistry insights. The time is now, as it is essential to enhance the productivity of our highly capital-intensive biotech/pharma R&D sector.

Medicinal R&D, however, is not to be underestimated as this is fundamentally a scientific challenge that is highly complex and multi-disciplinary. The delivery of new drugs requires the relentless pursuit of a pipeline of the highest caliber chemical tool compounds, Qualified Leads, preclinical IND-ready Drug Candidates, and phase-2-ready Drug Candidates that all feed into the ecosystem of pharma and biotech companies.

A new pipeline with these deliverables is enabled by the novel approaches to drug discovery chemistry AI being championed by the Institute for Molecular Intelligence™.

The work of the Institute for Molecular Intelligence™ develops potent, integrated drug discovery methods featuring an innovative in silico chemistry platform for Molecular Transmutation™. Designed to work on sets of genes, targets, and pathways in parallel, an integrated set of blended lab & computational platforms is deployed to yield medicinal advances.

Benefits include the delivery of potential new medicines to partner labs by harnessing decades of vital genomic and high-caliber chemical knowledge joined with physics and chemistry-informed 3D AI.

Mission: We pursue innovation with bold and creative drug discovery chemistry AI to empower the fight against Anti-Microbial Resistance, against both bacterial & fungal infections, and to accomplish this through accelerating an efficient attack on numerous microbiological targets in parallel.

Disease Focus:

Our disease focus on antimicrobials encompasses medicinal discovery vs. ESKAPE pathogens, and vs. TB and related NTM mycobacteria. Our methods for pursuit of Mechanism of Action (MoA) innovation will deliver new treatments for difficult fungal diseases.

A further chemical biology program (with a parallel computational/phenomenological strategy) will yield illumination of active modulators with currently unknown MoA in neurodegenerative disease.

Partnerships then extend the beneficial applications of the platform to far broader areas of human disease.

First and foremost is our focus on the strength and depth of our team with both proven scientific and practical experience, forged into one unit by a common commitment to the aims of this Focused Research Organization.

Growth of the members of the Institute over the upcoming periods will be carefully cultivated. Respect and camaraderie are featured elements, along with efficiency and focus. Dialog is vital, both internally as well as in skillful outreach across stakeholder communities.

Seasoned leadership brings experience in the biotech industry (and in Pfizer, Sanofi), leadership in government research (NCI, Frederick MD), and leadership of non-profit research labs.

The Institute is being designed with the ability to partner at all stages from fundamental chemical biology to the out-licensing of advanced Drug Candidates (NCEs) discovered internally through the Institute’s core methods.

Affiliates bring deep expertise in specialties ranging from BSL3 studies of pathogenic bacteria, including mycobacteria, and up through sophisticated functional models of neurodegenerative and other diseases.

The Institute can supply a highly selective molecular pipeline of innovative Qualified Leads to our expert Partners, delivered at a scale and quality that matches the throughput of those incisive and advanced information-rich disease-relevant assays.